RIGL

39.8603.23%
JW

Jane Wasman

Independent Director

Ms. Jane Wasman, J.D., had been an Independent Director of Director at Athersys, Inc. since November 2020 until April 1, 2024 & served as it's Independent Chairman since September 28, 2023 until April 1, 2024. Ms. Wasman is Founder and President of JWasman Advisors. She served as General Counsel and Corporate Secretary of Acorda Therapeutics, Inc. since May 2004 until December 2019. Ms. Wasman is a strategic leader with experience in the biopharma industry working with both large, multinational corporations and privately held start-ups. She served as President of International at Acorda Therapeutics, Inc. since October 09, 2012 until December 31, 2019. Ms. Wasman had been the Independent Chairman of SELLAS Life Sciences Group, Inc. since December 2017 until 2024 and serves as its Director since December 2017. She began her career as an attorney at two global law firms and was Associate Counsel for the U.S. Senate. Her early career provided broad industry experience, including industrial, financial, real estate and communications. Ms. Wasman served as the Chief of Strategic Development of Acorda Therapeutics, Inc. from January 2012 to October 2012. She also served as Executive Vice President of Acorda Therapeutics from May 2004 to January 2012. At Acorda, she led global strategic development, including long range planning and development, as well as international expansion and also built and led the Legal and Quality departments. From 1995 to 2004, Ms. Wasman held various leadership positions at Schering-Plough Corporation, including Staff Vice President and Associate General Counsel responsible for legal support for U.S. Pharmaceuticals operations, including sales, marketing and compliance; FDA regulatory matters; licensing and mergers and acquisitions; and global research and development. She served as Staff Vice President of International in 2001 and as Staff Vice President of European Operations-Legal from 1998 to 2000. Previously, Ms. Wasman specialized in litigation at Fried, Frank, Harris, Shriver & Jacobson, where she was involved in all aspects of commercial litigation, including securities, business fraud, environmental, product liability and commercial disputes. She has been Independent Director of Rigel Pharmaceuticals, Inc. since March 2019. She has been Member of the Board of Directors at New York Biotechnology Association Inc. since January 2008 and Biotie Therapies Corp. since May 11, 2016. She has been a member of the board of directors of the board of NewYorkBIO since February 22, 2007. She served as Director of Cytovia Therapeutics, Inc. until March 2022. Additionally, she is co-founder of the NY Hub of BioDirector, an organization supporting board effectiveness and diversity. She earned JD from Harvard Law School and her undergraduate degree from Princeton University, Magna Cum Laude and Phi Beta Kappa.

Positions